Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies
Jordan Gauthier(Seattle Cancer Care Alliance), Cameron J. Turtle(The University of Sydney), Erik L. Kimble(University of Washington), David G. Maloney(Fred Hutch Cancer Center), Andrew J. Cowan(University of Washington Medical Center), Aesha Vakil(Sana Biotechnology (United States)), Cassie Chou(University of Washington), Aude G. Chapuis(University of Washington), Evandro D. Bezerra(Cleveland Clinic), Brian G. Till(University of Washington), Alexandre V. Hirayama(University of Washington), Salvatore Fiorenza, Alyssa Sheih(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Mazyar Shadman(University of Washington), Filippo Milano(Fred Hutch Cancer Center), Hans‐Peter Kiem(Fred Hutch Cancer Center), Rachel N. Steinmetz, Abby W Jamieson, Merav Bar(Fred Hutch Cancer Center), Ryan D. Cassaday(University of Washington), Stanley R. Riddell(Fred Hutch Cancer Center), Tinh-Doan Phi, Damian J. Green(Sylvester Comprehensive Cancer Center), Barbara S. Pender, Reed M. Hawkins
Cited by 217
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Reconstitution of Cellular Immunity against Cytomegalovirus in Recipients of Allogeneic Bone Marrow by Transfer of T-Cell Clones from the Donor
|New England Journal of Medicine|1995|1.8k